investorscraft@gmail.com

Arcutis Biotherapeutics, Inc. (ARQT)

Previous Close
$13.82
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)73.42431
Intrinsic value (DCF)38.14176
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

3027 Townsgate Road
Westlake Village, CA 91361
United States
Phone: 805 418 5006
Industry: Biotechnology
Sector: Healthcare
CEO: Mr. Todd Franklin Watanabe M.A.
Full Time Employees: 342

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

HomeMenuAccount